You are here

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Maebashi Hirosegawa Clinic
Maebashi, Gunma, 371-0022 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypercholesterolemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population
A).

- Subjects who are naïve to a treatment by lipid lowering drug and whose LDL-C is not
controlled (Population B).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

- Pregnant females; breastfeeding females; males and females of childbearing potential;
males and females of childbearing potential who are unwilling or unable to use a
highly effective method of contraception.

- Subjects who were administered or prior exposed to PF-04950615 and/or anti-body
targeting PCSK9.

NCT02055976
Pfizer
Completed
Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now